Seattle Genetics to Present at Upcoming Investor Conference

Published on Wednesday, 07 December 2011 09:12 Written by TradersHuddle Staff

BOTHELL, Wash.-( Business Wire )-

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conference.

Oppenheimer 22^nd Annual Healthcare Conference

Wednesday, December 14, 2011 at 2:10 p.m. Eastern Time in New York, NY

The presentation will be webcast live and available for replay from Seattle Genetics’ website at http://www.seattlegenetics.com in the Investors and News section.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. ADCETRIS™ was approved by the FDA on August 19, 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.

Seattle Genetics, Inc.Peggy Pinkston, This e-mail address is being protected from spambots. You need JavaScript enabled to view it.